8-K: Aditxt Amends Evofem Merger Terms, Introduces New Preferred Stock

Aditxt, Inc. and Evofem Biosciences, Inc. have signed Amendment No. 6 to their merger agreement, adjusting key terms for shareholder approval, dissenting shares, and introducing new Series A-2 Convertible Preferred Stock.

Summary

• Aditxt, Inc., Adifem, Inc., and Evofem Biosciences, Inc. executed Amendment No. 6 to their Amended and Restated Merger Agreement on August 26, 2025.
• The amendment updates the definition of "Unconverted Company Preferred Stock" to include Evofem's Series G-1 Preferred Stock.
• "Company Shareholder Approval" now requires a majority vote from both outstanding Evofem common stock (including preferred stock with voting rights) and each series of unconverted Evofem preferred stock.
• Evofem will assist in obtaining Exchange Agreements for convertible notes and purchase rights, capped at not more than 89,021 shares of Parent Preferred Stock.
• The maximum number of dissenting shares is set at 5,932,818 common shares or 202 preferred shares.
• A new condition requires waivers from all holders of Evofem's Series E-1 Convertible Preferred Stock regarding specific provisions in their Certificate of Designations.
• The Certificate of Designation for the "Exchanged Parent Preferred Stock" (now Series A-2 Convertible Preferred Stock of Aditxt) has been replaced, detailing its rights and preferences, including a stated value of $1,000 per share and a blank conversion price.

Sentiment

Score: 6

Explanation: The amendment indicates continued progress towards the merger's completion by addressing specific structural and shareholder approval requirements. However, the need for multiple amendments and specific waivers suggests ongoing complexities and potential hurdles, preventing a higher score. The blank conversion price also adds a degree of uncertainty.

Positives

• The amendment clarifies and refines terms of the ongoing merger, indicating continued progress towards closing.
• The cap on preferred stock issued for exchange agreements (not more than 89,021 shares) provides clarity on potential dilution from this specific mechanism.
• Setting a maximum for dissenting shares (5,932,818 common, 202 preferred) provides a clearer threshold for the merger's viability.

Negatives

• The expanded requirement for "Company Shareholder Approval" to include each series of unconverted Evofem preferred stock could introduce additional complexity and potential hurdles to securing approval.
• The requirement for waivers from Series E-1 Convertible Preferred Stock holders suggests potential issues or triggers that needed to be addressed, indicating a need for specific concessions from these holders.
• The "Conversion Price" for the new Series A-2 Preferred Stock is left blank in the exhibit, which is a key financial term yet to be determined.

Risks

• Failure to obtain the required "Company Shareholder Approval" from both common and each series of unconverted preferred stock could prevent the merger from closing.
• Inability to secure waivers from all holders of Evofem's Series E-1 Convertible Preferred Stock could impede the merger's completion.
• The merger could be terminated if the number of dissenting shares exceeds the specified limits (5,932,818 common or 202 preferred).
• The ongoing nature of amendments suggests potential complexities or evolving conditions in the merger process.

Future Outlook

The filing indicates the ongoing progression of the merger between Aditxt and Evofem, with continued adjustments to terms and conditions to facilitate its completion by the extended End Date of September 30, 2025. The requirement for specific waivers and expanded shareholder approval suggests a path forward, albeit with additional conditions to be met.

Management Comments

• Parent, Merger Sub and the Company mutually desire to amend the Merger Agreement as provided below.
• The Parties, intending to be legally bound, hereby agree as follows.

Industry Context

This amendment is a routine, albeit detailed, step in a complex corporate merger within the biotechnology/pharmaceutical sector. Such adjustments are common as companies navigate regulatory requirements, shareholder approvals, and financial structuring during M&A processes. The focus on preferred stock and convertible notes suggests a financing-heavy transaction, typical for smaller biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders (Evofem): Will be subject to new, potentially more stringent, shareholder approval requirements for the merger. Holders of Series E-1 Convertible Preferred Stock will need to provide waivers for specific provisions.
• Shareholders (Aditxt): Will see the issuance of new Series A-2 Convertible Preferred Stock as part of the merger consideration, which could impact future capital structure and potential dilution.
• Convertible Noteholders (Evofem): Their exchange into Parent Preferred Stock is now capped at 89,021 shares, providing clarity on the maximum number of shares they will receive.

Next Steps

• Evofem to use commercially reasonable efforts to hold the Company Shareholders Meeting no later than September 26, 2025.
• Obtain "Company Shareholder Approval" as per the newly defined terms.
• Obtain waivers from each holder of Evofem's Series E-1 Convertible Preferred Stock.
• Complete the merger by the extended End Date of September 30, 2025.
• Determine the Conversion Price for the Series A-2 Convertible Preferred Stock.

Key Dates

Recommendation

The filing details ongoing adjustments to a complex merger agreement, indicating continued efforts to close the deal. While the amendments clarify certain terms and set thresholds, they also introduce new conditions (like expanded shareholder approval and specific waivers) that could still pose hurdles. The blank conversion price for the new preferred stock adds uncertainty. Given the ongoing nature and the mix of clarifying and potentially complicating factors, a 'hold' recommendation is appropriate as investors await further developments and the finalization of the merger terms.

Keywords

Aditxt, Evofem Biosciences, Merger Agreement, 8-K Filing, Corporate Acquisition, Preferred Stock, Shareholder Approval, Biotechnology, Pharmaceuticals, M&A, ADTX